Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
8 mg orally once daily, taken at bedtime.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
>99% bound to albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
4.9 L/kg (high distribution into tissues).
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral: 87% (tablet and solution); IM: 100%.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Known hypersensitivity to aripiprazole or any of its excipients.
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY vs BRISDELLE, answered by our medical review team.
ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY and BRISDELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.